Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Macro

Trump Announces New Tariffs on Pharmaceuticals, Trucks and Home Goods

by Team Lumida
September 26, 2025
in Macro
Reading Time: 4 mins read
A A
0
Trump Tariffs Leave Key Questions on China Supply Chain Rules Unanswered
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

Powered by lumidawealth.com

  • President Trump announced a series of tariffs effective Oct. 1, most notably a 100% tariff on branded/patented pharmaceutical products from companies that are not building manufacturing plants in the U.S.; other levies include 25% on heavy trucks, 50% on kitchen cabinets/vanities and 30% on upholstered furniture.
  • The pharma tariff is explicitly targeted at branded drugs (not generics), and the administration says companies building U.S. plants would be exempt; details, definitions and enforcement mechanisms are currently unclear.
  • The policy aims to accelerate onshoring of strategic manufacturing, but implementation complexity (content tracking, exemptions, treatment of assembled products) and legal/geopolitical pushback create material execution risk.
  • Market implications include potential margin pressure for import‑reliant OEMs and pharma companies that can’t or won’t re‑locate production, pricing effects in healthcare, and potential winners among U.S. domestic manufacturers and contractors that scale capacity.

What happened?

The president posted that, beginning Oct. 1, a 100% tariff will apply to branded or patented pharmaceutical products from companies not building U.S. manufacturing plants. The announcement — made alongside other industry levies — follows prior trade actions and incentives (e.g., the 2022 CHIPS Act) and comes amid a broader administration push to onshore critical industries. The White House has signaled exemptions for firms making credible U.S. capacity commitments, but it has not released detailed guidance on definitions, measurement or enforcement, leaving market participants to interpret near‑term exposure.

Why it matters

A 100% tariff on branded drugs, if broadly applied, materially changes the cost calculus for pharmaceutical supply chains and could raise U.S. list prices or compress manufacturer margins depending on who absorbs the levy; because branded drugs account for a meaningful share of pharmaceutical spending, the policy could feed healthcare cost inflation and prompt payers, PBMs and hospitals to renegotiate contracts. The announcement also creates a strong commercial incentive to accelerate U.S. factory builds, but capex cycles, technical complexity and local input costs mean many manufacturers may not be able to relocate quickly — creating near‑term uncertainty about which companies face tariff exposure. Outside pharma, tariffs on heavy trucks and furniture raise input costs for importers while benefiting domestic producers and may lead to higher consumer prices. Finally, the headline risk and legal ambiguity increase regulatory and political uncertainty — which markets dislike — and could trigger trade retaliation or litigation that further amplifies supply‑chain disruption.

What’s next

Watch for official rulemaking that defines “branded or patented pharmaceutical products,” the criteria for an exemption (what qualifies as “building a plant in America”), timing allowances, and the tariff calculation method for products with mixed domestic/foreign content. Track immediate corporate responses: public exemptions or accelerated U.S. investment pledges from drugmakers, procurement and sourcing announcements from OEMs (auto, electronics) and dealer/assembler contract renegotiations for trucks and furniture. Monitor short‑term market reactions in pharma, medical‑supplier, heavy‑truck and domestic‑manufacturing equities, and gauge potential inflation impact via drug price guidance, payer contract updates and CPI components for medical goods. Also follow legal and trade‑partner reactions — litigation or retaliatory tariffs could reshape outcomes and determine whether this moves from a headline threat to a durable policy that changes global sourcing.

Source
Previous Post

Microsoft Adds Anthropic Models to 365 Copilot

Next Post

Trump Advances Deal to Spin Out TikTok US

Recommended For You

Senate Passes the BAAJA Permitting Bill 62-33, Splitting Democrats, in a Push to Speed Energy and Data-Center Projects

by Team Lumida
19 hours ago

The Senate voted 62-33 on Thursday to pass the BAAJA permitting bill, which now heads to the House with President Donald Trump’s support.

Read more

Fed Governor Lisa Cook Says Inflation Has Been Above Target for More Than Five and a Half Years and Warns Against Waiting to Hike

by Team Lumida
19 hours ago

Lisa Cook said Friday that inflation has been above target for more than five and a half years and that waiting to raise rates risks larger increases later.

Read more

Gold Falls 2.81% to $3,520, Heading for Its Worst Week in Eight Months, Down About 8.9%, as Rate-Hike Bets Overwhelm Haven Demand

by Team Lumida
19 hours ago

Spot gold fell 2.81% to $3,520.05 on Friday, on track for its worst week in eight months, down about 8.9%, as December Fed hike bets weighed on bullion.

Read more

Treasury Yields Tumble, With the 10-Year Down 12 Basis Points to 4.932%, as Investors Flee to Havens Ahead of a Likely December Fed Hike

by Team Lumida
19 hours ago

The 10-year Treasury yield fell 12 basis points to 4.932% and the 2-year dropped more than 14 basis points to 4.634% as stocks sold off on Friday.

Read more

Gold Hovers Near $3,725, Close to Its Lowest Close Since September 2025, as Fed Minutes Show Nearly All Officials Expect More Rate Hikes

by Team Lumida
2 days ago

Gold traded near $3,725 an ounce, close to a 14-month low and down about 30% since the US-Iran war began, as the Fed signaled more rate hikes.

Read more

Foreign Holdings of US Treasuries Fall $75.5 Billion to $9.24 Trillion, the Biggest Drop Since March, Even as South Korean Investors Buy a Record $11.5 Billion

by Team Lumida
2 days ago

Foreign holdings of Treasuries fell $75.5 billion in September to a one-year low, led by China and France, while Korean investors bought a record amount.

Read more

Fed’s Waller Says the Fed May Need to ‘Shock People’ With a Half-Point Hike in December, Sending the 2-Year Treasury Yield Up More Than 4 Basis Points to 4.83%

by Team Lumida
3 days ago

Waller said a 50 basis point hike is probably needed at the Dec. 8-9 meeting, and the 2-year Treasury yield jumped more than 4 basis points to 4.83%.

Read more

Treasuries Gain for a Third Day as the 10-Year Yield Slips 3 Basis Points to 5.08%, With Traders Saying Much of the Fed’s Coming Rate Hikes Is Already Priced In

by Team Lumida
3 days ago

US Treasuries edged higher for a third day, with the 10-year yield down 3 basis points to 5.08% and the 2-year at 4.78%, as hike expectations look priced...

Read more

Iran Says It Struck U.S. Drone and Missile Sites in Kuwait as Gulf Attacks Mount, Yet WTI Settles Down 1.2% at $84.90 and Brent Slips to $92.70 on Recovering Hormuz Flows

by Team Lumida
3 days ago

Iran claimed strikes on U.S. sites in Kuwait as the war enters its ninth month, but crude settled lower on signs of recovering Hormuz flows.

Read more

Trump, Xi and Putin Converge on Shenzhen for APEC With a Trade Truce Expiring in January 2027, $30 Billion of Promised Tariff Cuts Unscheduled and Nvidia’s China Chip Scandal in the Background

by Team Lumida
3 days ago

Trump and Xi are expected to meet in Shenzhen this week to implement their trade deal, with Nvidia chips, tariffs and the Iran war all in play.

Read more
Next Post
person holding black iphone 5

Trump Advances Deal to Spin Out TikTok US

Alphabet $GOOGL Q2 2024 Results

TeraWulf Eyes ~$3B Debt Raise Backed by Google

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

a black square with a blue logo on it

Meta Charged by EU Over Handling of Illegal Content

October 24, 2025
Fed’s Waller: Stablecoins Are Extending the Reach of US Monetary Policy Worldwide

Fed’s Waller: Stablecoins Are Extending the Reach of US Monetary Policy Worldwide

June 1, 2026
The Four-Day Workweek: A Win-Win for Workers and Companies

The Four-Day Workweek: A Win-Win for Workers and Companies

June 2, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018